Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Long-Term Outcomes of Vedolizumab and TNF Inhibitors in Patients with Ulcerative Colitis

  • By

  • Siddharth Singh

  • Jonas Söderling

  • Anders Forss

  • Mathias Rask-Andersen

  • Jonas Halfvarson

  • Åsa H. Everhov

  • Jonas F. Ludvigsson

  • Ola Olén

  • SWIBREG study group

  • Malin Olsson

  • Pär Myrelid

  • Henrik Hjortswang

  • Jonas Bengtsson

  • Hans Strid

  • Marie Andersson

  • Susanna Jäghult

  • Caroline Nordenvall

  • Charlotte Hedin

  • Martin Rejler

  • Olof Grip

  • Ulrika L Fagerberg

  • Karl Mårild

  • Johann Hreinsson

  • Pontus Karling

  • September 25, 2026

Share

Original Source(s)

Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis

  • by Siddharth Singh, Jonas Söderling, Anders Forss, Mathias Rask-Andersen, Jonas Halfvarson, Åsa H. Everhov, Jonas F. Ludvigsson, Ola Olén, SWIBREG study group, Malin Olsson, Pär Myrelid, Henrik Hjortswang, Jonas Bengtsson, Hans Strid, Marie Andersson, Susanna Jäghult, Caroline Nordenvall, Charlotte Hedin, Martin Rejler, Olof Grip, Ulrika L Fagerberg, Karl Mårild, Johann Hreinsson, Pontus Karling

  • September 25, 2026

Related Content

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma

Medicaid Expansion and Mortality Among Patients With Colorectal Cancer

Efficacy and safety of Braun enteroenterostomy in patients undergoing pancreatoduodenectomy: a systematic review and meta-analysis